High copy-number cancers, such as serous tumors, account for 25% of high-grade endometrioid tumors and are characterized by high copy-number variability, a low mutation rate, frequent TP53 mutations, and poor estrogen and progesterone receptor expression. This evidence concerns the gene TP53 and endometrioid tumor.